… Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares LEIDEN, The Netherlands, … 2014. The offering was made only by means of a prospectus, copies of which may be obtained from Leerink Partners LLC, …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, the Netherlands … available on the SEC's website, located at www.sec.gov . Copies of the final prospectus supplement and the …
… of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares LEIDEN, Netherlands and … NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through …
Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases Company expects up to four clinical data readouts in 2025 and 2026 across multi
… pipeline program, QR-504a for Fuchs endothelial corneal dystrophy, is expected to advance to clinical testing in the … visual acuity, visual fields, and the objective measure of optical coherence tomography (OCT) retinal imaging, after a … The closing included the full exercise of underwriters’ option to purchase 2,076,923 additional shares. Gross …
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier, PhD nominated to Board with Annual General
AX-0810 program targeting NTCP for cholestatic diseases and AX-1412 program targeting B4GALT1 for cardiovascular diseases advancing to the clinic in late 2024/early 2025 with translational data and trial design details to be announced in H2 2024$4.5 million in milestones
… biomarker study for QR-504a for Fuchs endothelial corneal dystrophy to be reported in 2022 Cash runway into mid-to-late … individuals from the Phase 1/2 Stellar trial in the Helia open-label extension study, which will include multiple dose … data from this trial in 2022. ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) …
… the existing proven delivery technology to the liver, the opportunity to monitor early biomarkers to establish target … in human genetics with a significantly lower chance of developing cardiovascular disease. ProQR intends to advance … 8 th annual Oligonucleotide and Precision Therapeutics (OPT) Congress and at the bi-annual RNA Editing Gordon …